CIK 0001513525
- Non-accelerated filer
- Smaller reporting company
Azora Therapeutics, Inc. (DE)
Sign in to watch- Ticker
- AZR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 800667150
- Phone
- +1 434-422-9800
- Business address
- 16501 VENTURA BLVD, SUITE 400, ENCINO, CA, 91436
- Former names
- ADIAL PHARMACEUTICALS, INC., Adial Pharmaceuticals, L.L.C., ADial Pharmaceuticals, L.L.C.
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Executive Officer acquired 201,109 shares (grant or award)
- 4 Grant or award Director acquired 3,731 shares (grant or award)
- 4/A Derivatives Options or other derivatives
- 4/A Open-market buy Director bought 90,000 shares
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 350,000 shares at $1.21 ($423,500)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 19,644 shares at an average $1.36 ($26,769)
- 4 Open-market buy Chief Executive Officer bought 25,000 shares at an average $1.30 ($32,552)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Executive Officer acquired 54,167 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 27,084 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 150,000 shares at $1.00 ($150,000)
- 4 Grant or award Chief Medical Officer acquired 3,187 shares (grant or award)
Page 5 of 7 · 123 filings